NYSE:JNJPharmaceuticals
Should J&J’s Oncology and MedTech Breakthroughs Prompt a Fresh Look From Johnson & Johnson (JNJ) Investors?
Johnson & Johnson recently reported strong second-quarter 2026 results, lifted its full-year sales outlook to US$100.80 billion–US$101.40 billion, and announced positive Phase 3 MonumenTAL-6 data showing that TECVAYLI plus TALVEY and TALVEY plus pomalidomide improved progression-free and overall survival in relapsed or refractory multiple myeloma versus standard care.
Combined with De Novo FDA authorization for its OTTAVA table-integrated robotic surgical system, these advances highlight how...